



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/727,779	12/03/2003	Shea N. Gardner	IL-11191	7079

7590 08/02/2006

Eddie E. Scott
Assistant Laboratory Counsel
Lawrence Livermore National Laboratory
P.O. Box 808, L-703
Livermore, CA 94551

EXAMINER

BERTAGNA, ANGELA MARIE

ART UNIT	PAPER NUMBER
----------	--------------

1637

DATE MAILED: 08/02/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No. 10/727,779	Applicant(s) GARDNER ET AL.	
	Examiner Angela Bertagna	Art Unit 1637	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 07 June 2006.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-17 is/are pending in the application.
- 4a) Of the above claim(s) 1-10 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 11-17 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 03 December 2003 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date <u>12/3/2003</u> . | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Election/Restrictions

1. Applicant's election without traverse of Group II, claims 11-17 in the reply filed on June 7, 2006 is acknowledged.

Claims 1-10 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim.

Election was made **without** traverse in the reply filed on June 7, 2006.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Priority

2. Applicant's claim for the benefit of a prior-filed application under 35 U.S.C. 119(e) or under 35 U.S.C. 120, 121, or 365(c) is acknowledged. Applicant has not complied with one or more conditions for receiving the benefit of an earlier filing date under 35 U.S.C. 119(e) and 120 as follows: The later-filed application must be an application for a patent for an invention which is also disclosed in the prior application (the parent or original non-provisional application or provisional application). The disclosure of the invention in the parent application and in the later-filed application must be sufficient to comply with the requirements of the first paragraph of 35

Art Unit: 1637

U.S.C. 112. See *Transco Products, Inc. v. Performance Contracting, Inc.*, 38 F.3d 551, 32 USPQ2d 1077 (Fed. Cir. 1994).

The disclosures of the prior-filed applications, Application No. 10/394,337 and Provisional Application No. 60/428,579, fail to provide adequate support or enablement in the manner provided by the first paragraph of 35 U.S.C. 112 for one or more claims of this application. Specifically, neither application provides support for the instant claims 16 and 17, where the method is applied using n-mers of a size $n+1$, $n+2$, etc (claim 16), and where the method is applied using oligos in multiple reading frames (claim 17). For claims 16 and 17, the filing date of the instant application (December 3, 2003) has been used for prior art purposes.

Claim Rejections - 35 USC § 112

3. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 11-17 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 11 recites in the preamble “a method of fabricating a DNA molecule.” The method further recites steps of pre-selecting DNA segments, arraying fragments, temporal separation, and assembling groups into DNA molecules to produce a DNA molecule of a user-defined sequence. The “result” of the method is assembling groups to produce DNA molecules. The method does not actually recite a step of “fabricating” a DNA molecule. It is not clear whether “producing” a DNA molecule is intended to be an active, positive method step, and therefore the

Art Unit: 1637

intended relationship between the preamble and the method steps is unclear. As the intended limitation is not clear, claims 11-17 are indefinite.

Claim 11 recites a step of pre-selecting DNA segments by using computational techniques “to break ... sequence into fragments.” It is not clear whether a user-selected DNA is actually broken into fragments (*e.g.*, by an enzyme) or “virtually” broken in segments by applying a computer program to the user-defined DNA sequence. Further, claim 11 recites “arraying ... fragments into groups.” It is not clear whether the step intends to purify/separate actual DNA fragments into groups (*e.g.*, into different tubes, parts of an array, *etc.*) or “virtually” array fragments by using a computer program. As the relationship between the method steps is not clear, claims 11-17 are indefinite.

Claim Rejections - 35 USC § 102

4. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

(c) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

Art Unit: 1637

5. Claims 11, 14, 15, and 17 are rejected under 35 U.S.C. 102(b) as being anticipated by Selifonov, WO 00/42560 (published July 20, 2000).

Selifonov discloses a method of making polynucleotides having user-defined characteristics (see for a general description, pages 3-6 "Summary of Invention" and also page 9, lines 23-31).

Regarding claim 11, Selifonov discloses a method of fabricating a DNA molecule of user-defined sequence comprising:

(a) pre-selecting a multiplicity of DNA segments that will comprise a user-defined DNA molecule by using computational techniques to break the DNA molecule into fragments of defined size (page 14, lines 20-29; see also page 21, lines 12-22)

(b) arraying the fragments of defined size into groups (page 14, lines 27-30, where Selifonov teaches that the fragments may be left with the parental strands or transferred to a new population. Selifonov also teaches formation of new populations; see also page 21, lines 14-15 and lines 23-30, where sets are combined)

(c) separating the DNA sequence segments temporally (page 22, lines 4-19, where Selifonov teaches variation of the composition of fragments in the recombination reaction and/or performing multiple recombination reactions. This is a temporal separation of the DNA segments)

(d) assembling the groups into double-stranded DNA molecules of predetermined base-pairs using DNA polymerase to produce the DNA molecule of user-defined sequence (page 22, lines 12-13).

See also Figures 4A-D for a flow-chart depiction of the method of Selifonov.

Art Unit: 1637

Regarding claims 14 and 15, Selifonov teaches that the multiplicity of DNA segments comprise n-mers, where n is an even or odd number. Specifically, Selifonov teaches the use of DNA segments (or fragments) in the range of 10-20 nucleotides or more, 20-40 nucleotides or more, 40-60 nucleotides or more, 60-100 nucleotides or more 100-150 nucleotides or more, etc (page 6, lines 8-10) and further teaches variation of the oligo length (page 33, lines 5-6), thereby anticipating oligo lengths with an even or odd number of bases. Selifonov further teaches a specific example of oligos with a even number of bases (page 70, lines 18-19, where 40-mers are taught).

Regarding claim 17, Selifonov teaches that the multiplicity of DNA fragments comprises oligos in multiple reading frames. Specifically, Selifonov teaches variation of the oligo length and overlap between the fragmens (page 33, lines 1-6). These DNA fragments inherently comprise multiple reading frames.

6. Claims 11-15 are rejected under 35 U.S.C. 102(e) as being anticipated by Evans (US 2003/0087238 A1). This pre-grant publication was filed August 2, 2001.

Regarding claim 11, Evans discloses a method of fabricating a DNA molecule of user-defined sequence (see for a general description the abstract and paragraph 6) comprising:

(a) pre-selecting a multiplicity of DNA segments that will comprise a user-defined DNA molecule by using computational techniques to break the DNA molecule into fragments of defined size (see Figure 3 and paragraph 58)

(b) arraying the fragments of defined size into groups (paragraph 58 and Fig. 3; see also paragraphs 82 & 132 where fragments of defined size are taught)

(c) separating the DNA sequence segments temporally (paragraph 58 where Evans teaches sequential addition of the segments)

(d) assembling the groups into double-stranded DNA molecules of predetermined base-pairs using DNA polymerase to produce the DNA molecule of user-defined sequence (paragraphs 58 and 68).

Regarding claim 12, Evans teaches sequential addition of the DNA segments to form the user-defined sequence (paragraph 58). This requires a temporal separation of the DNA segments produced in step (a) above.

Regarding claim 13, Evans teaches that the DNA segments are added gradually, in sequence order (paragraph 58). Evans further teaches that the sequential addition minimizes errors (paragraph 66) and that computational techniques may be use to optimize (minimize errors) in the entire method (paragraph 178).

Regarding claims 14 and 15, Evans teaches that the multiplicity of DNA segments comprise n-mers, where n is an even or odd number. Specifically, Evans teaches numerous examples of oligonucleotides with an even and odd number of base pairs, for example 15 and 16 mers (see paragraph 53).

7. Claims 16 and 17 are rejected under 35 U.S.C. 102(a) and 102(e) as being anticipated by Evans (2003/0087238 A1; published May 8, 2003; filed August 2, 2001). As noted above, claims 16 and 17 have not been granted benefit of the earlier filing date of the previously filed provisional and non-provisional applications, but rather the instant application filing date of December 3, 2003.

Regarding claim 16, Evans teaches that the oligonucleotides may be different lengths (paragraph 53). Evans further teaches examples of oligonucleotides with lengths of 15 (n), 16 (n+1), 17 (n+2), etc (see paragraph 53).

Regarding claim 17, Evans teaches that the multiplicity of DNA fragments comprises oligos in multiple reading frames. Specifically, Evans teaches variation of the oligo length and overlap between the fragments (paragraphs 53 and 54). These DNA fragments inherently comprise multiple reading frames.

Claim Rejections - 35 USC § 103

8. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Art Unit: 1637

9. Claims 12 and 13 are rejected under 35 U.S.C. 103(a) as being unpatentable over Selifonov et al. (WO 00/42560) in view of Evans (US 2003/0087238 A1).

Selifonov teaches the method of claim 11, as discussed above.

Selifonov teaches computational modeling in an effort to minimize reassembly errors (see for example, page 10, lines 26-33).

However, Selifonov does not explicitly teach sequential addition of DNA segments in the reassembly process.

Evans teaches a method of synthesizing a user-defined nucleic acid sequence, as discussed above.

Regarding claims 12 and 13, Evans teaches that addition of the oligonucleotides in a sequential order (optimized by computational modeling) minimizes reassembly errors (see paragraphs 58, 66, and 178). Specifically, Evans states, "The sequential polynucleotide assembly methods of the invention further reduce the error rate observed with methods that require hybridization of pools of large numbers of oligonucleotides" (paragraph 66). Evans further states, "The sequential polynucleotide assembly methods of the invention eliminate the need for purification and allow for systematic assembly of identical sized double-stranded or single-stranded oligonucleotides" (paragraph 66).

It would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made to utilize the *in silico*-optimized sequential addition of DNA fragments taught by Evans in the nucleic acid synthesis method of Selifonov. Evans expressly taught the advantages of sequential addition of oligonucleotide segments in sequence order, namely: (1) a reduction in the assembly error rate, (2) elimination of the need for an extra purification step and

Art Unit: 1637

(3) parallel synthesis of identical-sized nucleic acids (see paragraph 66 and above). The ordinary practitioner would have been motivated by these teachings of Evans to sequentially add the fragments to the reassembly reaction in sequence order in order to improve the accuracy of the reassembly reaction, eliminate the need for further purification (thereby improving the speed and efficiency of the process), and obtain the ability to synthesize in parallel multiple, identically-sized nucleic acids.

10. Claim 16 is rejected under 35 U.S.C. 103(a) as being unpatentable over Selifonov et al. (WO 00/42560) in view of Murphy et al. (USPN 6,994,963).

Selifonov teaches the method of claim 11, as discussed above.

Selifonov teaches variation of DNA segment lengths and the use of a set of DNA segments comprising fragments of different lengths (see page 6, lines 8-10 and page 33, lines 1-6). However, Selifonov does not explicitly teach fragments of $n+1$, $n+2$, etc.

Murphy teaches a method of nucleic acid recombination. Briefly, the method of Murphy comprises primer extension and cleavage to create an “extension ladder” (column 4, lines 9-16) followed by recombinatorial synthesis to produce a mutagenized or chimeric nucleic acid (column 6, lines 34-40).

Regarding claim 16, Murphy teaches that the “extension ladder” (a collection of DNA segments) may comprise sequences of different length, specifically, sequences different by one nucleotide increments (i.e. n , $n+1$, $n+2$, etc) (see column 6, lines 49-56). Regarding the differently sized sequences, Murphy states, “Furthermore, the present invention may use a complete library of nucleic acid extension products that differ in length by a single base. As a

Art Unit: 1637

result, recombinatorial mutagenesis results in recombined sequences with potential crossover points at every single nucleotide in a nucleic acid sequence” (column 3, line 66 – column 4, line 4).

It would have been *prima facie* obvious for one of ordinary skill in the art at the time of invention to utilize DNA fragments differing by one nucleotide in length (n, n+1, n+2, etc) in the recombination method of Selifonov, since Murphy expressly taught that such a fragment pool resulted in “recombined sequences with potential crossover points at every single nucleotide in a nucleic acid sequence” (column 3, line 66 – column 4, line 4). The ordinary practitioner of the method of Selifonov would have been motivated by the teachings of Murphy to utilize the above length-diverse fragment pool in order to maximize the diversity of the resulting recombined/reassembled sequences, thereby improving the method’s ability to generate nucleic acids encoding proteins with improved functional properties.

Double Patenting

11. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned

Art Unit: 1637

with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

12. Claims 11 and 14-16 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 27 and 29-32 of copending Application No. 10/394,337 in view of Evans (US 2003/0087238 A1).

The instant claims 11 and 14-16 are drawn to a method of nucleic acid synthesis comprising computer-mediated fragmentation, arraying of fragments, temporal separation and polymerase-mediated reassembly. Claim 27 of the '337 application recites a highly similar but more specific (narrower) method, differing from the instant claims in its absence of the temporal separation step. Regarding the instant claims 14-16, claims 29-32 of the '337 application recite specific examples of n-mers where: (a) n is an even number (claims 29, 30, and 32 of the '337 application recite 4-mers, 6-mers, and 8-mers), (b) n is an odd number (claim 32 of the '337 application recites 5-mers), and (c) the n-mers are of a size n+1, n+2, etc (claim 32 of the '337 application recites 4-mers (n), 5-mers (n+1), and 6-mers (n+2)). To summarize, the primary difference between the more narrow claims of the '337 application and the instant claims is the absence of a temporal separation step in the '337 application.

As discussed above Evans teaches a method of nucleic acid synthesis comprising computer-mediated fragmentation, arraying of fragments, temporal separation and polymerase-mediated reassembly (see above). Regarding the temporal separation and subsequent sequential addition of fragments, Evans stated, "The sequential polynucleotide assembly methods of the invention further reduce the error rate observed with methods that require hybridization of pools

Art Unit: 1637

of large numbers of oligonucleotides” (paragraph 66). Evans further states, “The sequential polynucleotide assembly methods of the invention eliminate the need for purification and allow for systematic assembly of identical sized double-stranded or single-stranded oligonucleotides” (paragraph 66).

It would have been prima facie obvious to one of ordinary skill in the art at the time the invention was made to incorporate a temporal separation step as taught by Evans in the nucleic acid synthesis method claimed in the ‘337 application. Evans expressly taught the advantages of sequential addition of oligonucleotide segments in sequence order, namely: (1) a reduction in the assembly error rate, (2) elimination of the need for an extra purification step and (3) parallel synthesis of identical-sized nucleic acids (see paragraph 66 and above). The ordinary practitioner would have been motivated by these teachings of Evans to sequentially add the fragments to the reassembly reaction in sequence order in order to improve the accuracy of the reassembly reaction, eliminate the need for further purification (and thereby improve the speed and efficiency of the process), and obtain the ability to synthesize in parallel multiple, identically-sized nucleic acids.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Conclusion

Claims 11-17 are rejected. No claims are currently allowable.

Art Unit: 1637


Any inquiry concerning this communication or earlier communications from the examiner should be directed to Angela Bertagna whose telephone number is (571) 272-8291. The examiner can normally be reached on M-F 7:30-5 pm EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion can be reached on (571) 272-0782. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Angela Bertagna
Patent Examiner
Art Unit 1637

amb


JEFFREY FREDMAN
PRIMARY EXAMINER

7/27/06